UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates
04. November 2024 16:30 ET
|
Unity Biotechnology, Inc.
UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results
and Business Updates
UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024
24. September 2024 08:00 ET
|
Unity Biotechnology, Inc.
UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates
06. August 2024 16:30 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
14. Mai 2024 17:00 ET
|
Unity Biotechnology, Inc.
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates.
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
25. April 2024 08:00 ET
|
Unity Biotechnology, Inc.
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
15. April 2024 07:00 ET
|
Unity Biotechnology, Inc.
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates.
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
27. September 2023 07:00 ET
|
Unity Biotechnology, Inc.
Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more...
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
08. August 2023 16:05 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
21. Juni 2023 07:00 ET
|
Unity Biotechnology, Inc.
Phase 2b trial is a randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 (foselutoclax) compared to aflibercept over 24 weeks First novel...
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates
09. Mai 2023 16:05 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...